Cargando...
Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block
Pembrolizumab is a monoclonal antibody directed towards programmed cell death protein 1 (PD-1) and is an antineoplastic drug which has a growing variety of oncologic uses. Pembrolizumab is commonly associated with immune-related adverse events (IRAEs) but is infrequently noted to cause cardiotoxicit...
Guardado en:
| Publicado en: | Case Rep Cardiol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Hindawi
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007942/ https://ncbi.nlm.nih.gov/pubmed/32047674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8428210 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|